The FDA's approach to artificial intelligence has shifted from cautious observation to active engagement. In 2026, the agency is not merely reacting to AI innovation — it is proactively shaping how AI is developed, validated, and governed across the industries it regulates.
For companies in medical devices, pharmaceuticals, food safety, and cosmetics, understanding the FDA's AI strategy is no longer optional. It is a competitive necessity.
The FDA's Evolving AI Framework
The Scope Is Broader Than You Think
When most people think "FDA and AI," they picture medical devices — diagnostic algorithms, imaging analysis, clinical decision support. But the FDA's AI ambitions extend far beyond:
- Drug development: AI for target identification, clinical trial design, and manufacturing process optimization
- Food safety: Predictive analytics for contamination risk, supply chain monitoring, and import screening
- Regulatory operations: The FDA itself is using AI to prioritize inspections, analyze adverse event reports, and accelerate review processes
- Post-market surveillance: ML models that detect safety signals across real-world data sources
This means virtually every FDA-regulated company will encounter AI expectations — whether they are building AI systems or using AI-generated insights.
Three Pillars of the FDA's AI Strategy
The FDA's current approach rests on three pillars:
1. Transparency and Trust
The agency expects organizations to demonstrate that their AI systems are: - Explainable to regulators and end-users - Free from harmful biases - Validated using representative datasets - Subject to ongoing performance monitoring
This is not a checkbox exercise. The FDA wants to see evidence of a culture of AI transparency embedded in your organization's quality systems.
2. Lifecycle Governance
Static validation is no longer sufficient. The FDA expects AI systems to be governed across their full lifecycle: - Design and development with appropriate controls - Pre-market validation with rigorous testing protocols - Post-market monitoring with drift detection and revalidation triggers - Retirement with clear decommissioning procedures
This lifecycle approach mirrors the quality management system (QMS) framework that regulated companies already know — which is why integrating AI governance into your existing QMS is the most efficient path forward.
3. Collaboration and Standards
The FDA is actively collaborating with international regulators (Health Canada, MHRA, TGA) and standards organizations (ISO, IEEE) to harmonize AI requirements. This means: - ISO 42001 (AI Management Systems) is gaining regulatory recognition - NIST AI RMF principles are influencing FDA guidance - International convergence is creating a single set of expectations that multinational companies can build toward
What Changed in 2025-2026
Several concrete developments have accelerated the FDA's AI agenda:
Expanded AI/ML Device Authorizations
The FDA has now authorized over 1,000 AI/ML-enabled medical devices — a pace that is accelerating. The agency's experience with these submissions is informing more nuanced, risk-proportionate review approaches.
Computer Software Assurance (CSA)
The shift from Computer System Validation (CSV) to CSA has significant implications for AI systems. CSA's risk-based approach allows organizations to focus validation effort where it matters most — which, for AI systems, means emphasizing model performance monitoring over static testing documentation.
Digital Health Center of Excellence
The FDA's Digital Health Center of Excellence continues to expand its AI expertise and engagement with industry. This includes pre-submission programs that allow companies to discuss AI-related regulatory strategies before formal submissions.
Industry-Specific Implications
Medical Devices
For device manufacturers, the most immediate impact is on Software as a Medical Device (SaMD) classification and the PCCP framework. Key actions:
- Build PCCP documentation into your design and development process from day one
- Establish model performance monitoring as a post-market surveillance activity
- Train your regulatory affairs team on AI-specific submission requirements
Pharmaceuticals and Biotech
AI in pharma touches GxP environments, which adds complexity. Key actions:
- Validate AI/ML models to the same rigor as analytical methods in regulatory submissions
- Ensure 21 CFR Part 11 compliance for AI systems generating electronic records
- Document model development decisions with the same traceability expected for manufacturing processes
Food and Cosmetics
AI adoption in food safety and cosmetics regulation is earlier-stage but accelerating. Key actions:
- Monitor FDA's evolving use of predictive analytics in import screening — your AI capabilities should complement the agency's
- Prepare for AI-assisted inspection targeting, which means your compliance data should be audit-ready
Building Your FDA AI Strategy
Organizations that succeed with FDA-regulated AI share common characteristics:
- Cross-functional governance: AI decisions involve quality, regulatory, data science, legal, and operations — not just the data science team
- Integrated management systems: AI governance is built into existing QMS frameworks, not operated as a parallel system
- Proactive regulatory engagement: Early conversations with FDA through pre-submission programs reduce surprises during review
- Documentation as a discipline: Every model decision, training data choice, and validation result is documented to audit-ready standards
- Continuous monitoring: Model performance is tracked in production, with defined triggers for revalidation
How We Help
Navigating the FDA's AI landscape requires expertise that spans regulatory affairs, quality management, and AI governance. At Regulated AI Consulting, this intersection is our specialization.
- AI Risk Assessment: Evaluate your AI portfolio against current FDA expectations
- AI Governance Design: Build management systems that satisfy both FDA requirements and ISO 42001
- Fractional Chief AI Officer: Embedded leadership for organizations that need ongoing AI governance expertise without a full-time hire
Schedule a consultation to discuss your FDA AI strategy.
Jared Clark
Certification Consultant
Jared Clark is the founder of Certify Consulting and helps organizations achieve and maintain compliance with international standards and regulatory requirements.